Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7506199 | 0.92 | CA2 (0.52) | CA2CA1CA12CA4CA6 | |
| SCHEMBL21651095 | 0.89 | CA2 (0.52) | CA2CA1CA12CA4CA6 | |
| SCHEMBL7515457 | 0.88 | CA2 (0.47) | CA2CA1CA12CA4CA6 | |
| SCHEMBL7518760 | 0.87 | CA2 (0.58) | CA2CA1CA12CA4CA6 | |
| SCHEMBL7510619 | 0.87 | CA2 (0.58) | CA2CA1CA12CA4CA6 | |
| SCHEMBL4787923 | 0.87 | CA2 (0.50) | CA2CA1CA12CA4CA6 | |
| SCHEMBL7509743 | 0.87 | CA2 (0.51) | CA2CA1CA12CA4CA6 | |
| SCHEMBL7515419 | 0.86 | CA2 (0.56) | CA2CA1CA12CA4CA6 | |
| SCHEMBL7509432 | 0.86 | CA2 (0.56) | CA2CA1CA12CA4CA6 | |
| SCHEMBL4750415 | 0.85 | CA2 (0.64) | CA2CA1CA12CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059802-B2 | Carbonic anhydrase targeting agents and methods of using same | VISEN MEDICAL, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-2707102-B1 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20190300501-A1 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL, INC. | 2019-10-03 | — | — | US | disclosed |
| EP-0527801-A4 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | — | 1993-03-10 | — | — | EP | disclosed |
| EP-0527801-A1 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | ALCON LABORATORIES, INC. (US) | 1993-02-24 | — | — | EP | disclosed |
| WO-1991015486-A1 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | ALCON LABORATORIES, INC. (US) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300501-A1 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | CA4, CA12, CA9 | CA2 4/4885CA1 7/4885CA12 2/4885 |
| US-11059802-B2 | Carbonic anhydrase targeting agents and methods of using same | CA4, CA12, CA9 | CA2 4/4885CA1 7/4885CA12 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.